Yale Cancer Center researchers have identified high expression levels of the detoxifying lactonase PON2 in B-cell acute lymphoblastic leukemia (B-ALL) cells as a mechanism to facilitate the energy production to promote leukemic transformation. PON2 enables glucose-uptake activity of the glucose transporter 1 by releasing the transporter from its inhibitor.
"PON2 was critical for glucose uptake and energy production and loss of PON2 prevented leukemia development," said Markus Müschen, senior author of the study published in PNAS today. "High levels of PON2 did not only predict poor outcomes of leukemia patients in clinical trials, but it also contributes to a more aggressive course of disease."
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
Researchers noted findings from this study provide new insights into B-cell metabolism as well as B-ALL biology and highlight the significance of glucose and energy supply in leukemic transformation. "From a treatment perspective, the study suggests that the enzyme activity of PON2 can be leveraged to selectively kill B-ALL cells," added Müschen. "Targeting of PON2 could be developed as a novel therapeutic intervention strategy to overcome drug-resistance in B-ALL."